Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& q% F0 l9 {! ]3 R7 S
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
) v! [0 q3 [5 Z! u9 J+ Author Affiliations
2 d+ I7 Z& f- i- M5 T$ w7 \
( }# d9 \% r2 x5 `" d1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan , a0 W5 b6 v$ s1 d5 G
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
) t5 I, n. X( ^ w- P; j& h3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan # m7 R0 Z. f' J; S$ F8 L% U4 H
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan * }# J5 {( S) H+ C8 g! N
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 3 M' w3 X7 h- d. m* B( m
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
4 N# c, [/ ?) L: \; i* O1 w* P: u& k7Kinki University School of Medicine, Osaka 589-8511, Japan
# `8 Z8 @. l5 P9 Y1 L8Izumi Municipal Hospital, Osaka 594-0071, Japan
4 w7 ?) f. b7 _. l9 V' d6 e9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan * e$ D" u6 S0 S. ~' w! C
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
7 H! W1 a- F3 M+ fAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. & G( Z( o: n4 I: I9 ^
* o* j8 f$ n$ @5 t |